SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 30, 2010
SINOBIOPHARMA, INC.
(Exact Name of Registrant as Specified in Charter)
|
Nevada
|
333-144910
|
26-3002371
|
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
|
of Incorporation)
|
Identification No.)
|
|
8 Zhong Tian Road,
Nantong City, Jiangsu Province, People’s Republic of China 226009
|
|
(Address of Principal Executive Offices)
|
Registrant's telephone number, including area code: (86) 51-385328336
Copies to:
Gregory Sichenzia, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
As previously reported on Sinobiopharma, Inc.’s (the “Company”) Current Report on Form 8-K filed on June 30, 2010, on May 30, 2010, the board of directors of the Company resolved that the company would issue Ms. Hoki Luk 300,000 shares of the Company’s common stock as compensation for serving as an independent director.
On December 30, 2010, the board of directors approved, and Ms. Luk agreed, to waive her rights to the 300,000 shares and instead receive $10,000 in cash, to be paid on or before January13, 2011, in full satisfaction of compensation for her services as independent director.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
None.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: December 30, 2010
|
||
|
SINOBIOPHARMA, INC.
|
||
|
By:
|
/s/ Lequn Huang
|
|
|
Lequn Huang
|
||
|
Chief Executive Officer
|
||
3